GLP-1受容体作動薬の市場規模、シェア、動向分析レポート：製品別、用途別、投与経路別、地域別、セグメント予測、2025年～2030年

GLP-1受容体作動薬市場の成長と動向

Grand View Research, Inc.の最新レポートによると、GLP-1受容体作動薬の世界市場規模は2030年までに1,567億1,000万米ドルに達し、2025～2030年にかけて17.46%のCAGRで拡大すると予測されています。

強力な製品パイプラインと製剤の進歩が市場を牽引しています。さらに、斬新な革新的製品が市場を活気づけています。2019年9月、最初で唯一の経口GLP-1アナログであるRybelsusが、2型糖尿病患者の血糖コントロール改善薬として米国FDAに承認されました。同剤はノボノルディスク社が開発したセマグルチドを主成分とする製品で、現在、欧州医薬品庁（EMA）と医薬品医療機器庁（PMDA）の審査を受けています。承認取得後、市場は予測期間中に大きく成長する可能性があります。

さらに、製薬企業は新しいGLP-1製品を開発するための研究協力に注力しています。例えば、2018年9月、Eli Lilly and CompanyはChugai Pharmaceutical Co., LtdとOWL833に関するライセンス契約を締結しました。OWL833は中外製薬独自の経口GLP-1作動薬候補であり、契約に基づきEli Lillyは世界の商業化権と開発権を取得します。

両社は現在、売上高を拡大するために地理的拡大を目指しています。Novo Nordiskはノースカロライナ州にある製造部門に投資することで事業を拡大しています。同社はGLP-1受容体作動薬の市場シェアの約50.0%を占めており、予測期間中、市場を独占すると予想されます。さらに、2018年7月、Sanofiは、世界リーチを強化するための研究開発拠点設立のため、中国に約7,410万米ドルを投資しました。

各社はまた、既存製品のライフサイクルを向上させるため、米国FDAや欧州、中東、アフリカなどの当局による肥満や主要有害心血管イベントなどの他の適応症の承認取得にも注力しています。例えば、2020年1月、Novo Nordisk社は、2型糖尿病患者における主要心血管有害事象（MACE）を適応症とするオゼンピックの米国FDA承認を取得しました。

GLP-1受容体作動薬市場のレポートハイライト

• オゼンピックセグメントが市場を独占し、2024年のシェアは34.17%。オゼンピックは、成人の2型糖尿病の治療に使用される米国FDA承認の配合薬のブランド名です。
• ゼップバウンドは、2025～2030年にかけて大きなCAGRで成長すると予想されています。この成長は、世界の医薬品承認と、その高い有効性と忍容性による高い需要に起因します。
• 2024年には2型糖尿病セグメントが市場を独占し、予測期間のCAGRは17.06%で成長すると予測されます。
• 非経口セグメントは2024年に最大のシェアを占め、2025～2030年にかけてCAGR 17.42％で成長すると予測されます。
• 病院薬局セグメントは2024年に55.09%の最大シェアを占めました。病院薬局の成長は、複数の医療コンポーネントの統合を促進し、糖尿病や肥満の診察のための入院患者の訪問を増加させ、GLP-1薬を入手する際の顧客の利便性を向上させました。
• 北米のGLP-1受容体作動薬市場は、2024年に77.72%のシェアを占めました。北米のGLP-1受容体作動薬市場は、リラグルチド（ビクトーザ）、デュラグルチド（トゥリシティ）、エキセナチド（バイエッタ/バイドゥレオン）、セマグルチド（オゼンピック）などの既存ブランドが圧倒的なシェアを占めています。
• アジア太平洋のGLP-1受容体作動薬市場は、世界市場で最も速い成長が見込まれています。同地域の医療セクターの成長、対象人口の多さ、アンメットニーズの高さなどが、大きな成長の可能性をもたらすと予測されています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 GLP-1受容体作動薬市場の変数、動向、範囲

• 市場系統の展望
  • 親市場の展望
  • 関連/付随市場の展望
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• GLP-1受容体作動薬市場分析ツール
  • 産業分析-ポーターのファイブフォース分析
  • PESTEL分析
• 価格分析
• パイプライン分析
• 特許失効分析

第4章 GLP-1受容体作動薬市場：製品別、推定・動向分析

• 世界のGLP-1受容体作動薬市場：製品ダッシュボード
• 世界のGLP-1受容体作動薬市場：製品の変動分析
• オゼンピック
• リュベルスス
• トルリシティ
• サクセンダ
• ウェゴヴィ
• ヴィクトザ
• ムンジャロ
• ゼップバウンド
• その他

第5章 GLP-1受容体作動薬市場：用途別、推定・動向分析

• 世界のGLP-1受容体作動薬市場：用途ダッシュボード
• 世界のGLP-1受容体作動薬市場：用途の変動分析
• 2型糖尿病
• 肥満

第6章 GLP-1受容体作動薬市場：投与経路別、推定・動向分析

• 世界のGLP-1受容体作動薬市場：投与経路ダッシュボード
• 世界のGLP-1受容体作動薬市場：投与経路の変動分析
• 非経口
• 経口

第7章 GLP-1受容体作動薬市場：流通チャネル別、推定・動向分析

• 世界のGLP-1受容体作動薬市場：流通チャネルダッシュボード
• 世界のGLP-1受容体作動薬市場：流通チャネルの変動分析
• 病院薬局
• 小売薬局
• オンライン薬局

第8章 GLP-1受容体作動薬市場：製品、用途、投与経路、流通チャネルによる地域別、推定・動向分析

• 地域ダッシュボード
• 市場規模と予測動向分析、2018～2030年
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • デンマーク
  • スウェーデン
  • ノルウェー
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第9章 競合情勢

• 企業/競合の分類
• 参加者概要
• Financial Overview
• 企業市場シェア分析、2024年
• 戦略マッピング
• 企業プロファイル
  • Eli Lilly and Company.
  • Sanofi
  • Novo Nordisk A/S
  • AstraZeneca.

List of Tables

• Table 1 Index of Tables
• Table 2 List of key distributors and channel partners
• Table 3 List of key emerging companies'/technology disruptors/innovators
• Table 4 North America GLP-1 Receptor Agonist Market, by Country, 2018 - 2030 (USD Million)
• Table 5 North America GLP-1 Receptor Agonist Market, by Product, 2018 - 2030 (USD Million)
• Table 6 North America GLP-1 Receptor Agonist Market, by Application, 2018 - 2030 (USD Million)
• Table 7 North America GLP-1 Receptor Agonist Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 8 North America GLP-1 Receptor Agonist Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 9 U.S. GLP-1 Receptor Agonist Market, by Product, 2018 - 2030 (USD Million)
• Table 10 U.S. GLP-1 Receptor Agonist Market, by Application, 2018 - 2030 (USD Million)
• Table 11 U.S.GLP-1 Receptor Agonist Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 12 U.S. GLP-1 Receptor Agonist Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 13 Canada GLP-1 Receptor Agonist Market, by Product, 2018 - 2030 (USD Million)
• Table 14 Canada GLP-1 Receptor Agonist Market, by Application, 2018 - 2030 (USD Million)
• Table 15 Canada GLP-1 Receptor Agonist Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 16 Canada GLP-1 Receptor Agonist Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 17 Mexico GLP-1 Receptor Agonist Market, by Product, 2018 - 2030 (USD Million)
• Table 18 Mexico GLP-1 Receptor Agonist Market, by Application, 2018 - 2030 (USD Million)
• Table 19 Mexico GLP-1 Receptor Agonist Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 20 Mexico GLP-1 Receptor Agonist Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 21 Europe GLP-1 Receptor Agonist Market, by Country, 2018 - 2030 (USD Million)
• Table 22 Europe GLP-1 Receptor Agonist Market, by Product, 2018 - 2030 (USD Million)
• Table 23 Europe GLP-1 Receptor Agonist Market, by Application, 2018 - 2030 (USD Million)
• Table 24 Europe GLP-1 Receptor Agonist Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 25 Europe GLP-1 Receptor Agonist Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 26 Germany GLP-1 Receptor Agonist Market, by Product, 2018 - 2030 (USD Million)
• Table 27 Germany GLP-1 Receptor Agonist Market, by Application, 2018 - 2030 (USD Million)
• Table 28 Germany GLP-1 Receptor Agonist Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 29 Germany GLP-1 Receptor Agonist Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 30 UK GLP-1 Receptor Agonist Market, by Product, 2018 - 2030 (USD Million)
• Table 31 UK GLP-1 Receptor Agonist Market, by Application, 2018 - 2030 (USD Million)
• Table 32 UK GLP-1 Receptor Agonist Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 33 UK GLP-1 Receptor Agonist Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 34 France GLP-1 Receptor Agonist Market, by Product, 2018 - 2030 (USD Million)
• Table 35 France GLP-1 Receptor Agonist Market, by Application, 2018 - 2030 (USD Million)
• Table 36 France GLP-1 Receptor Agonist Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 37 France GLP-1 Receptor Agonist Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 38 Italy GLP-1 Receptor Agonist Market, by Product, 2018 - 2030 (USD Million)
• Table 39 Italy GLP-1 Receptor Agonist Market, by Application, 2018 - 2030 (USD Million)
• Table 40 Spain GLP-1 Receptor Agonist Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 41 Italy GLP-1 Receptor Agonist Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 42 Spain GLP-1 Receptor Agonist Market, by Product, 2018 - 2030 (USD Million)
• Table 43 Spain GLP-1 Receptor Agonist Market, by Application, 2018 - 2030 (USD Million)
• Table 44 Denmark GLP-1 Receptor Agonist Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 45 Spain GLP-1 Receptor Agonist Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 46 Denmark GLP-1 Receptor Agonist Market, by Product, 2018 - 2030 (USD Million)
• Table 47 Denmark GLP-1 Receptor Agonist Market, by Application, 2018 - 2030 (USD Million)
• Table 48 Denmark GLP-1 Receptor Agonist Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 49 Denmark GLP-1 Receptor Agonist Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 50 Sweden GLP-1 Receptor Agonist Market, by Product, 2018 - 2030 (USD Million)
• Table 51 Sweden GLP-1 Receptor Agonist Market, by Application, 2018 - 2030 (USD Million)
• Table 52 Sweden GLP-1 Receptor Agonist Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 53 Sweden GLP-1 Receptor Agonist Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 54 Norway GLP-1 Receptor Agonist Market, by Product, 2018 - 2030 (USD Million)
• Table 55 Norway GLP-1 Receptor Agonist Market, by Application, 2018 - 2030 (USD Million)
• Table 56 Norway GLP-1 Receptor Agonist Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 57 Norway GLP-1 Receptor Agonist Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 58 Asia Pacific GLP-1 Receptor Agonist Market, by Country, 2018 - 2030 (USD Million)
• Table 59 Asia Pacific GLP-1 Receptor Agonist Market, by Product, 2018 - 2030 (USD Million)
• Table 60 Asia Pacific GLP-1 Receptor Agonist Market, by Application, 2018 - 2030 (USD Million)
• Table 61 Asia Pacific GLP-1 Receptor Agonist Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 62 Asia Pacific GLP-1 Receptor Agonist Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 63 Japan GLP-1 Receptor Agonist Market, by Product, 2018 - 2030 (USD Million)
• Table 64 Japan GLP-1 Receptor Agonist Market, by Application, 2018 - 2030 (USD Million)
• Table 65 Japan GLP-1 Receptor Agonist Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 66 Japan GLP-1 Receptor Agonist Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 67 China GLP-1 Receptor Agonist Market, by Product, 2018 - 2030 (USD Million)
• Table 68 China GLP-1 Receptor Agonist Market, by Application, 2018 - 2030 (USD Million)
• Table 69 China GLP-1 Receptor Agonist Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 70 China GLP-1 Receptor Agonist Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 71 India GLP-1 Receptor Agonist Market, by Product, 2018 - 2030 (USD Million)
• Table 72 India GLP-1 Receptor Agonist Market, by Application, 2018 - 2030 (USD Million)
• Table 73 India GLP-1 Receptor Agonist Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 74 India GLP-1 Receptor Agonist Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 75 Australia GLP-1 Receptor Agonist Market, by Product, 2018 - 2030 (USD Million)
• Table 76 Australia GLP-1 Receptor Agonist Market, by Application, 2018 - 2030 (USD Million)
• Table 77 Australia GLP-1 Receptor Agonist Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 78 Australia GLP-1 Receptor Agonist Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 79 South Korea GLP-1 Receptor Agonist Market, by Product, 2018 - 2030 (USD Million)
• Table 80 South Korea GLP-1 Receptor Agonist Market, by Application, 2018 - 2030 (USD Million)
• Table 81 South Korea GLP-1 Receptor Agonist Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 82 South Korea GLP-1 Receptor Agonist Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 83 Thailand GLP-1 Receptor Agonist Market, by Product, 2018 - 2030 (USD Million)
• Table 84 Thailand GLP-1 Receptor Agonist Market, by Application, 2018 - 2030 (USD Million)
• Table 85 Thailand GLP-1 Receptor Agonist Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 86 Thailand GLP-1 Receptor Agonist Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 87 Latin America GLP-1 Receptor Agonist Market, by Country, 2018 - 2030 (USD Million)
• Table 88 Latin America GLP-1 Receptor Agonist Market, by Product, 2018 - 2030 (USD Million)
• Table 89 Latin America GLP-1 Receptor Agonist Market, by Application, 2018 - 2030 (USD Million)
• Table 90 Latin America GLP-1 Receptor Agonist Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 91 Latin America GLP-1 Receptor Agonist Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 92 Brazil GLP-1 Receptor Agonist Market, by Product, 2018 - 2030 (USD Million)
• Table 93 Brazil GLP-1 Receptor Agonist Market, by Application, 2018 - 2030 (USD Million)
• Table 94 Brazil GLP-1 Receptor Agonist Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 95 Brazil GLP-1 Receptor Agonist Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 96 Argentina GLP-1 Receptor Agonist Market, by Product, 2018 - 2030 (USD Million)
• Table 97 Argentina GLP-1 Receptor Agonist Market, by Application, 2018 - 2030 (USD Million)
• Table 98 Argentina GLP-1 Receptor Agonist Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 99 Argentina GLP-1 Receptor Agonist Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 100 MEA GLP-1 Receptor Agonist Market, by Country, 2018 - 2030 (USD Million)
• Table 101 MEA GLP-1 Receptor Agonist Market, by Product, 2018 - 2030 (USD Million)
• Table 102 MEA GLP-1 Receptor Agonist Market, by Application, 2018 - 2030 (USD Million)
• Table 103 South Africa GLP-1 Receptor Agonist Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 104 MEA GLP-1 Receptor Agonist Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 105 South Africa GLP-1 Receptor Agonist Market, by Product, 2018 - 2030 (USD Million)
• Table 106 South Africa GLP-1 Receptor Agonist Market, by Application, 2018 - 2030 (USD Million)
• Table 107 South Africa GLP-1 Receptor Agonist Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 108 South Africa GLP-1 Receptor Agonist Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 109 Saudi Arabia GLP-1 Receptor Agonist Market, by Product, 2018 - 2030 (USD Million)
• Table 110 Saudi Arabia GLP-1 Receptor Agonist Market, by Application, 2018 - 2030 (USD Million)
• Table 111 Saudi Arabia GLP-1 Receptor Agonist Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 112 Saudi Arabia GLP-1 Receptor Agonist Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 113 UAE GLP-1 Receptor Agonist Market, by Product, 2018 - 2030 (USD Million)
• Table 114 UAE GLP-1 Receptor Agonist Market, by Application, 2018 - 2030 (USD Million)
• Table 115 UAE GLP-1 Receptor Agonist Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 116 UAE GLP-1 Receptor Agonist Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 117 Kuwait GLP-1 Receptor Agonist Market, by Product, 2018 - 2030 (USD Million)
• Table 118 Kuwait GLP-1 Receptor Agonist Market, by Application, 2018 - 2030 (USD Million)
• Table 119 Kuwait GLP-1 Receptor Agonist Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 120 Kuwait GLP-1 Receptor Agonist Market, by Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 GLP-1 Receptor Agonist Market segmentation
• Fig. 2 Market research process
• Fig. 3 Information procurement
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value chain-based sizing & forecasting
• Fig. 7 QFD modelling for market share assessment
• Fig. 8 GLP-1 Receptor Agonist Market snapshot (2024)
• Fig. 9 GLP-1 Receptor Agonist Market: Segment snapshot (2024)
• Fig. 10 Competitive Insights (2024)
• Fig. 11 Parent market outlook
• Fig. 12 Related/ancillary market outlook
• Fig. 13 GLP-1 Receptor Agonist Market driver impact
• Fig. 14 GLP-1 Receptor Agonist Market restraint impact
• Fig. 15 Porter's Five Forces Analysis
• Fig. 16 SWOT Analysis, By Factor (Political & legal Economic and technological)
• Fig. 17 Strategic alliance analysis
• Fig. 18 Recent developments & impact analysis, by key market participants
• Fig. 19 Key company market share analysis, 2024
• Fig. 20 Company market position analysis
• Fig. 21 Definition and scope, by product
• Fig. 22 Product market share analysis, 2024 & 2030
• Fig. 23 Segment dashboard
• Fig. 24 Global GLP-1 Receptor Agonist Market, by product, 2018 - 2030 (USD Million)
• Fig. 25 Ozempic market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 26 Rybelsus market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 27 Trulicity market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 28 Saxenda market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 29 Mounjaro market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 30 Victoza market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 31 Zepbound market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 32 Wegovy market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 33 Other market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 34 Definition and scope, by Application
• Fig. 35 Application market share analysis, 2024 & 2030
• Fig. 36 Segment dashboard.
• Fig. 37 Global GLP-1 Receptor Agonist Market, by Application, 2018 - 2030 (USD Million)
• Fig. 38 Type 2 diabetes mellitus market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 39 Obesity market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 40 Definition and scope by route of administration
• Fig. 41 Route of administration market share analysis, 2024 & 2030
• Fig. 42 Segment dashboard.
• Fig. 43 Global GLP-1 Receptor Agonist Market, by Route of Administration, 2018 - 2030 (USD Million)
• Fig. 44 Parenteral market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 45 Oral market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 46 Definition and scope, by distribution channel
• Fig. 47 Distribution channel market share analysis, 2024 & 2030
• Fig. 48 Segment dashboard.
• Fig. 49 Global GLP-1 Receptor Agonist Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Fig. 50 Hospital pharmacies market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 51 Retail pharmacies market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 52 Online pharmacies market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 53 North America market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 54 U.S. market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 55 Canada market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 56 Mexico market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 57 Europe market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 58 UK market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 59 Germany market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 60 Spain market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 61 France market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 62 Italy market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 63 Sweden market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 64 Denmark market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 65 Norway market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 66 Asia Pacific market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 67 China market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 68 Japan market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 69 India market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 70 Australia market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 71 South Korea market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 72 Thailand market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 73 Latin America market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 74 Brazil market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 75 Argentina market size, & forecasts and trend analysis, 2018 to 2030 (USD Million))
• Fig. 76 Middle East and Africa market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 77 South Africa market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 78 Saudi Arabia market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 79 UAE market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
• Fig. 80 Kuwait market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)

GLP-1 Receptor Agonist Market Growth & Trends:

The global GLP-1 receptor agonist market size is expected to reach USD 156.71 billion by 2030, expanding at a CAGR of 17.46% from 2025 to 2030, according to a new report by Grand View Research, Inc. The strong product pipeline and formulation advancements are driving the market. In addition, novel innovative products are booming the market. In September 2019, Rybelsus, the first and only oral GLP-1 analog was approved by the U.S.FDA for improving the glycemic control in type-2 diabetes patients. It is a semaglutide-based product developed by Novo Nordisk, which is currently under review by European Medicines Agency (EMA) and Pharmaceuticals and Medical Devices Agency (PMDA). After receiving the approval, the market may witness significant growth over the forecast period.

Furthermore, pharmaceutical companies are focusing on research collaborations for developing new GLP-1 products. For instance, in September 2018, Eli Lilly and Company entered into a license agreement with Chugai Pharmaceutical Co., Ltd for OWL833. OWL833 is Chugai's proprietary oral GLP-1 agonist candidate and as per the agreement Eli Lilly will obtain global commercialization and development rights.

The companies are currently aiming on geographical expansion for increasing the sales output. Novo Nordisk is expanding its business by investing in the manufacturing unit located in North Carolina. The company holds around 50.0% of the market share of GLP-1 receptor agonists and is expected to dominate the market over the forecast period. Furthermore, in July 2018, Sanofi invested about USD 74.1 million in China for establishing an R&D hub to enhance its global reach.

The companies are also focusing on getting approval for other indications like obesity and major adverse cardiovascular events by authorities like the U.S.FDA, EMEA, and others for the existing products to increase their life cycle. For instance, in January 2020, Novo Nordisk received the U.S. FDA approval for Ozempic for Major Adverse Cardiovascular Events (MACE) in type 2 diabetes patients.

GLP-1 Receptor Agonist Market Report Highlights:

• The ozempic segment dominated the market and accounted for a share of 34.17% in 2024. Ozempic is a brand-name U.S. FDA-approved prescription drug used to treat adults with type 2 diabetes.
• Zepbound is expected to grow at a significant CAGR from 2025 to 2030. This growth can be attributed to its worldwide approval of a drug and high demand due to its high efficacy and tolerability.
• The type 2 diabetes mellitus segment dominated the market in 2024 and is expected to grow at a CAGR of 17.06% over the forecast period.
• The parenteral segment held the largest share in 2024 and is expected to grow at a CAGR of 17.42% from 2025 to 2030.
• The hospital pharmacies segment held the largest share of 55.09% in 2024. The growth of hospital pharmacies has facilitated the integration of several healthcare components, increased inpatient visits for diabetes and obesity consultations, and improved customer convenience in acquiring GLP-1 medications.
• North America GLP-1 receptor agonist market accounted for a 77.72% share in 2024. Established brands including liraglutide (Victoza), dulaglutide (Trulicity), exenatide (Byetta/Bydureon), and semaglutide (Ozempic) dominate the GLP-1 receptor agonist market in North America.
• Asia Pacific GLP-1 receptor agonists market is anticipated to witness the fastest growth in the global market. The region's growing healthcare sector, sizable target population, and high unmet clinical needs are some factors projected to provide significant growth potential.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Application
  • 1.2.3. Route of Administration
  • 1.2.4. Distribution Channel
  • 1.2.5. Regional scope
  • 1.2.6. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product and Application Outlook
  • 2.2.2. Route of Administration and Distribution Channel outlook
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. GLP-1 Receptor Agonist Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing prevalence of chronic diseases such as diabetes and obesity
    • 3.2.1.2. Increasing R&D activities for developing novel therapeutics
    • 3.2.1.3. Formulation advancements of oral GLP-1 receptor agonists
    • 3.2.1.4. Increasing awareness about diagnosis and treatment options for diabetes
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Product failure
    • 3.2.2.2. Patent expiry of blockbuster drugs during the forecast period
• 3.3. GLP-1 Receptor Agonist Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
• 3.4. Pricing Analysis
• 3.5. Pipeline Analysis
• 3.6. Patent Expiry Analysis

Chapter 4. GLP-1 Receptor Agonist Market: Product Estimates & Trend Analysis

• 4.1. Global GLP-1 Receptor Agonist Market: Product Dashboard
• 4.2. Global GLP-1 Receptor Agonist Market: Product Movement Analysis
• 4.3. Ozempic
  • 4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.4. Rybelsus
  • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Trulicity
  • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Saxenda
  • 4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Wegovy
  • 4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.8. Victoza
  • 4.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.9. Mounjaro
  • 4.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.10. Zepbound
  • 4.10.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.11. Others
  • 4.11.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. GLP-1 Receptor Agonist Market: Application Estimates & Trend Analysis

• 5.1. Global GLP-1 Receptor Agonist Market: Application Dashboard
• 5.2. Global GLP-1 Receptor Agonist Market: Application Movement Analysis
• 5.3. Type 2 Diabetes Mellitus
  • 5.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.4. Obesity
  • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. GLP-1 Receptor Agonist Market: Route of Administration Estimates & Trend Analysis

• 6.1. Global GLP-1 Receptor Agonist Market: Route of Administration Dashboard
• 6.2. Global GLP-1 Receptor Agonist Market: Route of Administration Movement Analysis
• 6.3. Parenteral
  • 6.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 6.4. Oral
  • 6.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. GLP-1 Receptor Agonist Market: Distribution Channel Estimates & Trend Analysis

• 7.1. Global GLP-1 Receptor Agonist Market: Distribution Channel Dashboard
• 7.2. Global GLP-1 Receptor Agonist Market: Distribution Channel Movement Analysis
• 7.3. Hospital Pharmacies
  • 7.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 7.4. Retail Pharmacies
  • 7.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Online Pharmacies
  • 7.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. GLP-1 Receptor Agonist Market: Regional Estimates & Trend Analysis By Product, Application, Route of Administration, and Distribution Channel

• 8.1. Regional Dashboard
• 8.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030
• 8.3. North America
  • 8.3.1. U.S.
    • 8.3.1.1. Key country dynamics
    • 8.3.1.2. Regulatory framework/ reimbursement structure
    • 8.3.1.3. Competitive scenario
    • 8.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.3.2. Canada
    • 8.3.2.1. Key country dynamics
    • 8.3.2.2. Regulatory framework/ reimbursement structure
    • 8.3.2.3. Competitive scenario
    • 8.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.3.3. Mexico
    • 8.3.3.1. Key country dynamics
    • 8.3.3.2. Regulatory framework/ reimbursement structure
    • 8.3.3.3. Competitive scenario
    • 8.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 8.4. Europe
  • 8.4.1. UK
    • 8.4.1.1. Key country dynamics
    • 8.4.1.2. Regulatory framework/ reimbursement structure
    • 8.4.1.3. Competitive scenario
    • 8.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.2. Germany
    • 8.4.2.1. Key country dynamics
    • 8.4.2.2. Regulatory framework/ reimbursement structure
    • 8.4.2.3. Competitive scenario
    • 8.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.3. France
    • 8.4.3.1. Key country dynamics
    • 8.4.3.2. Regulatory framework/ reimbursement structure
    • 8.4.3.3. Competitive scenario
    • 8.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.4. Italy
    • 8.4.4.1. Key country dynamics
    • 8.4.4.2. Regulatory framework/ reimbursement structure
    • 8.4.4.3. Competitive scenario
    • 8.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.5. Spain
    • 8.4.5.1. Key country dynamics
    • 8.4.5.2. Regulatory framework/ reimbursement structure
    • 8.4.5.3. Competitive scenario
    • 8.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.6. Denmark
    • 8.4.6.1. Key country dynamics
    • 8.4.6.2. Regulatory framework/ reimbursement structure
    • 8.4.6.3. Competitive scenario
    • 8.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.7. Sweden
    • 8.4.7.1. Key country dynamics
    • 8.4.7.2. Regulatory framework/ reimbursement structure
    • 8.4.7.3. Competitive scenario
    • 8.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.8. Norway
    • 8.4.8.1. Key country dynamics
    • 8.4.8.2. Regulatory framework/ reimbursement structure
    • 8.4.8.3. Competitive scenario
    • 8.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 8.5. Asia Pacific
  • 8.5.1. Japan
    • 8.5.1.1. Key country dynamics
    • 8.5.1.2. Regulatory framework/ reimbursement structure
    • 8.5.1.3. Competitive scenario
    • 8.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.2. China
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework/ reimbursement structure
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.3. India
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Regulatory framework/ reimbursement structure
    • 8.5.3.3. Competitive scenario
    • 8.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.4. Australia
    • 8.5.4.1. Key country dynamics
    • 8.5.4.2. Regulatory framework/ reimbursement structure
    • 8.5.4.3. Competitive scenario
    • 8.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.5. South Korea
    • 8.5.5.1. Key country dynamics
    • 8.5.5.2. Regulatory framework/ reimbursement structure
    • 8.5.5.3. Competitive scenario
    • 8.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.6. Thailand
    • 8.5.6.1. Key country dynamics
    • 8.5.6.2. Regulatory framework/ reimbursement structure
    • 8.5.6.3. Competitive scenario
    • 8.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 8.6. Latin America
  • 8.6.1. Brazil
    • 8.6.1.1. Key country dynamics
    • 8.6.1.2. Regulatory framework/ reimbursement structure
    • 8.6.1.3. Competitive scenario
    • 8.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.2. Argentina
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework/ reimbursement structure
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 8.7. MEA
  • 8.7.1. South Africa
    • 8.7.1.1. Key country dynamics
    • 8.7.1.2. Regulatory framework/ reimbursement structure
    • 8.7.1.3. Competitive scenario
    • 8.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.2. Saudi Arabia
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework/ reimbursement structure
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.3. UAE
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Regulatory framework/ reimbursement structure
    • 8.7.3.3. Competitive scenario
    • 8.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.4. Kuwait
    • 8.7.4.1. Key country dynamics
    • 8.7.4.2. Regulatory framework/ reimbursement structure
    • 8.7.4.3. Competitive scenario
    • 8.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Company/Competition Categorization
• 9.2. Participant Overview
• 9.3. Financial Overview
• 9.4. Product Benchmarking
• 9.5. Company Market Share Analysis, 2024
• 9.6. Strategy Mapping
• 9.7. Company Profiles
  • 9.7.1. Eli Lilly and Company.
    • 9.7.1.1. Company overview
    • 9.7.1.2. Financial performance
    • 9.7.1.3. benchmarking
    • 9.7.1.4. Strategic initiatives
  • 9.7.2. Sanofi
    • 9.7.2.1. Company overview
    • 9.7.2.2. Financial performance
    • 9.7.2.3. benchmarking
    • 9.7.2.4. Strategic initiatives
  • 9.7.3. Novo Nordisk A/S
    • 9.7.3.1. Company overview
    • 9.7.3.2. Financial performance
    • 9.7.3.3. benchmarking
    • 9.7.3.4. Strategic initiatives
    • 9.7.3.5.
  • 9.7.4. AstraZeneca.
    • 9.7.4.1. Company overview
    • 9.7.4.2. Financial performance
    • 9.7.4.3. benchmarking
    • 9.7.4.4. Strategic initiatives